Table 2.

Characteristics of the healthy population used for lisinopril PBPK model development

Population Ethnicity	Population Size (n)	Proportion of female	Age (years)	Dose (mg)	Application	References
European	12	0	21–34	2.97	Single IV bolus	[41]
				5.53
				11.20
Caucasians	18	0	21–37	20	Single oral dose	[42]
European	28	0	18–42	20	Single oral dose	[26]
European	8	0	22–31	20	Single oral dose for 10 days	[41]
Neonates to Infants	100	50	0.25–1.0	5	Single oral dose	Current study
				2.5
				1.5
Neonates to toddler	100	50	0.25–1.9	20	Single oral dose
				10
				5
				2.5
				1.5
Pre-schools children	100	50	2–5	20	Single oral dose
				10
				5
				2.5
				1.5
School children	100	50	5–12	20	Single oral dose
				10
				5
				2.5
				1.5
Adolescent	100	50	12–16	20	Single oral dose
				10